000403 Pacific Shuanglin Bio-pharmacy
- 28.06
- -1.48-5.01%
Pacific Shuanglin Bio-pharmacy News
Pacific Shuanglin Bio-pharmacy (SZSE:000403) Seems To Use Debt Quite Sensibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to consider debt, when you think about how risky any given stock is, because too much
Huaxin Securities: Both the supply and demand sides of blood products continue to improve, and the scale effect of leading companies gradually emerges.
According to the research reports released by Huaxin Securities, with the support and attention of domestic policies, the planning of new plasma stations such as the "14th Five-Year Plan" will gradually be implemented, and the construction of plasma stations will accelerate. China's plasma collection scale will continue to increase. In 2023, the plasma collection volume will exceed 12079 tons, an increase of more than 18.6% compared with 2022. Blood products belong to essential pharmaceuticals, and the entire industry is a licensed business, which determines its natural high policy barrier characteristics. The scale of plasma collection, the comprehensive utilization rate of blood plasma, and the profit-making ability of blood plasma are the core factors. The scale of plasma collection directly determines the scale of the enterprise. The number of existing varieties and research products are used to determine the comprehensive utilization rate and profit-making ability of blood plasma.
Morgan Stanley Starts Pacific Shuanglin Bio-pharmacy at Overweight With 37 Yuan Price Target
12:13 AM EDT, 05/27/2024 (MT Newswires) -- Morgan Stanley Starts Pacific Shuanglin Bio-pharmacy at Overweight With 37 Yuan Price Target Price (RMB): ¥26.18, Change: ¥-0.52, Percent Change: -1.95%
We Ran A Stock Scan For Earnings Growth And Pacific Shuanglin Bio-pharmacy (SZSE:000403) Passed With Ease
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story even if these companies are loss-making. But as Peter Lynch said in One Up On Wall
Pacific Shuanglin Bio-pharmacy's Unit Gets Nod to Trial Intravenous Human Immunoglobulin
Pacific Shuanglin Bio-pharmacy's (SHE:000403) unit, Guangdong Shuanglin Biopharmaceutical, will conduct clinical trails on its intravenous human immunoglobulin after obtaining approval of China's Nati
Pailin Biotech (000403.SZ): Intravenous human immunoglobulin (10%) approved for clinical trials
Zhitong Finance App News, Pailin Biotech (000403.SZ) announced that Guangdong Shuanglin Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, has received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration. The name of the relevant drug is intravenous human immunoglobulin (10%), and it has agreed to carry out clinical trials with primary immune thrombocytopenia as the indication.
Yang Feng, shareholder of Pailin Biotech (000403.SZ), completed a reduction of 5.9985 million shares
Zhitong Finance App News, Pailin Biotech (000403.SZ) announced that Yang Feng, the shareholder of the company, reduced his holdings of the company's shares by a total of 5.9985 million shares, accounting for 0.82% of the total share capital. The implementation of this holdings reduction plan has been completed.
Pacific Shuanglin Bio-pharmacy Subsidiary Gets Plasmapheresis License
Pacific Shuanglin Bio-pharmacy's (SHE:000403) subsidiary Jixi Donghai Pacific Plasma Apheresis obtained a plasmapheresis license from health authorities in Heilongjiang province, China, according to a
Pailin Biotech (000403.SZ): Guangdong Shuanglin Phase II Project is expected to be put into operation in the second half of 2025, and the annual production capacity will increase to 1,500 tons
Gelonghui, May 9, 丨 Pailin Biotech (000403.SZ) held a performance briefing on May 7, 2024. Regarding “the expected increase in production capacity after the Guangdong Shuanglin production workshop construction project is put into operation,” the company replied that the Guangdong Shuanglin Phase II project is expected to be put into operation in the second half of 2025, and the annual production capacity will increase to 1,500 tons.
Pailin Biotech (000403.SZ): Slurry harvesting target is 1,400 tons in 2024
Gelonghui, May 9丨Pailin Biotech (000403.SZ) held a performance briefing on May 7, 2024. Regarding “How much plasma the company collects in 2023, how much plasma is expected to be collected in 2024?” The company replied that in 2023, the company's pulp collection volume will exceed 1,200 tons, and the scale of pulp collection will rank first in the kiloton level in the blood products industry; the target amount of pulp collection in 2024 is 1,400 tons.
Pailin Biotech (000403.SZ): Jixi Plasma Station obtained a single plasma collection license
On May 8, Ge Longhui (000403.SZ) announced that Jixi Donghai Pasfique Single Plasma Collection Co., Ltd. (“Jixi Pulp Station”), a wholly-owned subsidiary of the company, has received a “Single Plasma Collection License” issued by the Heilongjiang Provincial Health Commission.
Pailin Biotech (000403.SZ): Net profit of 122 million yuan in the first quarter increased 116.31% year-on-year
Gelonghui, April 26 | Pailin Biotech (000403.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 436 million yuan, up 67.00% year on year; net profit attributable to shareholders of listed companies was 122 million yuan, up 116.31% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 108 million yuan, up 196.85% year on year; basic earnings per share were 0.1669 yuan
Pailin Biotech (000403.SZ): Yi'an Plasma Station obtained a single plasma collection license
On April 15, Gelonghui (000403.SZ) announced that Yi'an Pasfik Single Plasma Collection Co., Ltd. (“Yi'an Plasma Station”), a wholly-owned subsidiary of the company, has received a “Single Plasma Collection License” issued by the Heilongjiang Provincial Health Commission.
Pacific Shuanglin Bio-pharmacy Seen More Than Doubling in Q1; Shares Up 3%
Pacific Shuanglin Bio-pharmacy (SHE:000403) expects to log an attributable net profit attributable of between 112.8 million yuan and 129.7 million yuan in the first quarter of 2023, soaring up to 130%
Pailin Biotech (000403.SZ) Performance Report: 2023 net profit of 612 million yuan increased 4.25% year-on-year
Gelonghui, April 12 | Pailin Biotech (000403.SZ) announced the 2023 annual results report. During the reporting period, the company achieved total operating income of 2,329 billion yuan, a year-on-year decrease of 3.18%; net profit attributable to shareholders of listed companies of 612 million yuan, an increase of 4.25% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of 565 million yuan, an increase of 9.08% year on year; and basic earnings per share.
Pailin Biotech (000403.SZ): Baiquan Plasma Station obtained a single plasma collection license
On March 25, Gelonghui (000403.SZ) announced that Baiquan Paisfique Single Plasma Collection Co., Ltd. (“Baiquan Pulp Station”), a wholly-owned subsidiary of the company, has received a “Single Plasma Collection License” issued by the Heilongjiang Provincial Health Commission.
Pailin Biotech (000403.SZ): Guangdong Shuanglin signed an exclusive license and supply agreement with 3A
Gelonghui, March 20 | Pailin Biotech (000403.SZ) announced that Guangdong Shuanglin Biopharmaceutical Co., Ltd. (“Guangdong Shuanglin”), a wholly-owned subsidiary of the company, has received an intravenous human immunoglobulin (pH4) drug registration certificate wholesale from the National Health Service, Regulation and Coordination Ministry of the Pakistan Government and the Pakistan Drug Administration. The specification is intravenous human immunoglobulin (pH4) 2.5g (5%), 50ml. After obtaining a drug registration certificate, it can be exported and sold in the Pakistani market. Recently, Pakistani distributors 3ADIagnoA( “3A” for short) and Guang
Pailin Biotech (000403.SZ): Shareholder Yang Feng plans to reduce his holdings by no more than 0.82%
On February 28, Ge Longhui (000403.SZ) announced that Ms. Yang Feng, the shareholder of the company, and her co-actors held a total of 126,426,249 shares of the company, accounting for 17.25% of the company's total share capital. Among them, Ms. Yang Feng held 10,399,172 shares of the company, accounting for 1.42% of the company's total share capital. It is planned that within six months after 15 trading days from the date of disclosure of the announcement, Ms. Yang Feng, the shareholder of the company, will reduce her holdings of the company's shares by no more than 6,000,000 shares (inclusive) through centralized bidding or bulk transactions, accounting for 0.82% of the company's total share capital.
Pailin Biotech (000403.SZ)'s 478.49 million restricted shares can be listed and circulated on February 27
Pailin Biotech (000403.SZ) announced that the number of shares the company has lifted sales restrictions this time is 478.49 million shares, accounting for...
There's Reason For Concern Over Pacific Shuanglin Bio-pharmacy Co., LTD's (SZSE:000403) Price
Pacific Shuanglin Bio-pharmacy Co., LTD's (SZSE:000403) price-to-earnings (or "P/E") ratio of 34.8x might make it look like a sell right now compared to the market in China, where around half of the
Analysis
Price Target
No Data
